Development of cytarabine prodrugs and delivery systems for leukemia treatment

Expert Opinion on Drug Delivery

Volumn 7, Issue 12, 2010, Pages 1399-1414

  Chhikara, Bhupender S ^a   Parang, Keykavous ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

amino acid; arabinofuranosylcytosine; araC; chitosan; cytarabine; delivery system; fatty acid cytarabine; liposome; nanoparticle; prodrug

Indexed keywords

ARA C 5' ELAIDIC ACID ESTER; CHITOSAN; CLORETAZINE; CP 4055; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; CYTARABINE DERIVATIVE; ELACYT; FATTY ACID DERIVATIVE; GEMCITABINE; IDARUBICIN; IRINOTECAN; LIPOSOME; NANOPARTICLE; NIOSOME; POLYMER; TOPOTECAN; UNCLASSIFIED DRUG; ZIDOVUDINE;

CANCER THERAPY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG STABILITY; DRUG UPTAKE; HUMAN; HYDROGEL; LEUKEMIA; LIPOSOMAL DELIVERY; LYMPHOMA; MENINGITIS; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CYTARABINE; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; PRODRUGS;

EID: 78649937348     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.527330     Document Type: Review

References (97)

1. Meeker ND, Yang JJ, Schiffman JD. Pharmacogenomics of pediatric acute lymphoblastic leukemia. Expert Opin Pharmacother 2010;11(10):1621-32
2. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72
3. The Leukemia and Lymphoma Society, Facts 2009-2010. Available from: attachments/National/br-1247234696. pdf [Last accessed 15 July 2010]
4. Fullmer A, OBrien S, Kantarjian H, Jabbour E. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 2010;15(1):1-11
5. Cilloni D, Messa E, Rotolo A, Saglio G. Emerging drugs for chronic myeloid leukemia. Expert Opin Emerg Drugs 2010;15(2):175-84
6. Harris TJR, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010;7(5):251-65
7. Kumar L, Vikram P, Kochupilla V. Recent advances in the management of multiple myeloma. Nat Med J Ind 2006;19(2):80-9
8. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 2009;6(3):285-304
9. Fernandez HF, Rowe JM. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Cur Opin Hematol 2010;17(2):79-84
10. Arya LS. Acute lymphoblastic leukemia: current treatment concepts. Ind Pediatrics 2000;37(4):397-406
11. Hoogstraten B, Glidewell O, Holland JF, et al. Long term follow-up of combination chemotherapy-radiotherapy of stage III Hodgkins disease: a Cancer and Acute Leukemia Group B study. Cancer 1979;43(4):1234-44
12. Kumar R, Shandal V, Shamim SA, et al. Clinical applications of PET and PET/ CT in pediatric malignancies. Expert Rev Anticancer Ther 2010;10(5):755-68
13. Jabbour E, Cortes JE, Giles FJ, et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007;109(11):2171-81
14. Shah M, Agarwal B. Recent advances in management of acute myeloid leukemia (AML). Ind J Pediat 2008;75(8):831-37
15. Pinilla-Ibarz J, Bello C. Modern approaches to treating chronic myelogenous leukemia. Cur Oncol Rep 2008;10(5):365-71
16. Matsumura I. Standard therapies for acute myeloid leukemia. Rinsho Ketsueki 2009;50(10):1389-400
17. Mayer RJ, Davis RB, Schiffer CA. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903
18. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009;31(2):2349-70
19. Abali H, Urun Y, Oksuzoglu B, et al. Comparison of ICE (ifosfamidecarboplatin- etoposide) versus DHAP (cytosine arabinoside- cisplatindexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26(4):401-6
20. Petit J, Boque C, Cancelas JA, et al. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leuk Lymphoma 1999;34(1-2):119-27
21. Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma 2009;50(5):716-22
22. Suzuki K, Nakazato T, Sanada Y, et al. Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma. Rinsho Ketsueki 2010;51(3):207-12
23. Kantarjian HM, OBrien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18(3):547-61
24. Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 1987;14:159-66
25. Cohen SS. The lethality of aranucleotides. Med Biol 1976;54(5):299-326
26. Capizzi RL, White JC, Powell BL,Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 1991;28(4):54-69
27. Slevin ML, Piall EM, Aherne GW, et al. Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion. Cancer Chemother Pharmacol 1983;10(2):112-14
28. Stella VJ, Charman WN, Naringrekar VH. Prodrugs. Do they have advantages in clinical practice? Drugs 1985;29:455-73
29. Harper NJ. Drug latentiation. Prog Drug Res 1962;4:221-94
30. Sinkula AA, Yalkowsky SH. Rationale for design of biologically reversible drug derivatives: prodrugs. J Pharm Sci 1975;64:181-210
31. Peterson LW, McKenna CE. Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin Drug Deliv 2009;6(4):405-20
32. Ali M, Hariharan AG, Mishra N, Jain S. Catalytic antibodies as potential therapeutics. Ind J Biotech 2009;8(3):253-58
33. Jin MJ, Hong JH, Han HK. Synthesis and in vivo evaluation of N4-amino acid derivatives of cytarabine for improving the oral delivery of cytarabine. J Korean Pharm Sci 2008;38(4):255-9
34. Sun Y, Sun J, Shi L, et al. Synthesis, transport and pharmacokinetics of 5-amino acid ester prodrugs of 1-beta-Darabinofuranosylcytosine. Mol Pharm 2009;6(1):315-25
35. Li F, Maag J, Alfredson H. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 2008;97(3):1109-34
36. Nam NH, Sardari S, Selecky M, Parang K. Carboxylic acid and phosphate ester derivatives of fluconazole: Synthesis and antifungal activities. Bioorg Med Chem 2004;12(23):6255-69
37. Liu B, Cui C, Duan W, et al. Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta- arabinofuranosylcytosine. Eur J Med Chem 2009;44:3596-600
38. Bergman AM, Kuiper CM, Voorn DA, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukaemia and solid tumour cell lines. Biochem Pharmacol 2004;67:503-11
39. Breistol K, Balzarini J, Sandvold ML, et al. Antitumour activity of P-4055 (Elaidic Acid-Cytarabine) compared to cytarabine in metastatic and s.c. human tumour xenograft models. Cancer Res 1999;59:2944-9
40. Ross DD, Chen SR, Cuddy DP. Effects of 1-beta-Darabinofuranosylcytosine on DNA replication intermediates monitored by PH-step alkaline elution. Cancer Res 1990;50:2658-66
41. Bergman AM, Kuiper CM, Myhren F, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukaemia and solid tumour cell lines. Nucleosides Nucleotides Nucleic Acids 2004;23:1523-6 (Pubitemid 39625956)
42. Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol 2009;144(2):273-5
43. Adams DJ, Sandvold ML, Myhren F, et al. Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 2008;49(4):786-97
44. Dueland S, Aamdal S, Lind MJ, et al. Intravenous administration of CP-4055 (ElacytTM) in patients with solid tumours. A phase 1 study. Acta Oncol 2009;48:137-45
45. Chhikara BS, Mandal D, Parang K. Synthesis and evaluation of fatty acyl ester derivatives of cytarabine as anti-leukemia agents. Eur J Med Chem 2010;45(10):4601-8
46. Peterson LW, McKenna CE. Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin Drug Deliv 2009;6(4):405-20
47. Hong CI, Nechaev A, West CR. Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-b-Darabinofuranosylcytosine conjugates of prednisolone and prednisone. J Med Chem 1979;22:1428-32
48. Raetz CRH, Chu MY, Srivastava SP, Turcotte JG. A phospholipid derivative of cytosine arabinoside and its conversion to phosphatidylinositol by animal tissue. Science 1977;196:303-5
49. Rosowsky A, Kim SH, Ross J, Wick MM. Lipophilic 5¢-alkyl phosphate esters of 1-beta-Darabinofuranosylcytosine and its N4-acyl and 2,2¢-anhydro-3¢-O-acyl derivatives as potential prodrugs. J Med Chem 1982;25:171-8
50. MacCoss M, Ryu EK, Matsushita T. The synthesis, characterization, and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine-5¢- diphosphate-L-1,2-dipalmitin. Biochem Biophys Res Commun 1978;85:714-23
51. Yoshida Y, Yamada J, Watanabe T, et al. Participation of the peroxisomal beta-oxidation system in the chain shortening of PCA16, a metabolite of the cytosine arabinoside prodrug, YNKO1, in rat liver. Biochem Pharmacol 1990;39:1505-12
52. Saneyoshi M, Morozumi M, Kodama K, et al. Synthetic nucleosides and nucleotides. XVI. Synthesis and biological evaluations of a series of 1-beta-D-arabinofuranosylcytosine 5¢-alkyl or arylphosphates. Chem Pharm Bull 1980;28:2915-23
53. Schleyer E, Braess J, Ramsauer B, et al. Pharmacokinetics of Ara-CMP-stearate (YNK01): phase I study of the oral Ara-C derivative. Leukemia 1995;9:1085-90
54. Ueda T, Kamiya K, Urasaki Y, et al. Clinical pharmacology of 1-beta-Darabinofuranosylcytosine- 5¢- stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D- arabinofuranosylcytosine. Cancer Res 1994;54:109-13
55. Braess J, Freund M, Hanauske A, et al. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkins lymphoma phase I/II studies and pharmacokinetics. Leukemia 1998;12:1618-26
56. Heussner P, Willemze R, Ganser A, et al. YNK01, an oral cytosine arabinoside derivative in acute myeloid leukemia and chronic myeloid leukemia. Haematol Blood Transfus 1997;38:882-5
57. Snow B. Drug information: a guide to current resources. 1999, Chapter 15. 2nd edition. Maryland: Scarecrow Press, Inc. pp. 456-64
58. Gouy MH, Jordheim LP, Lefebvre I, et al. Special features of mixed phosphotriester derivatives of cytarabine. Bioorg Med Chem 2009;17:6340-47. This article reports a study of comparative enzymatic hydrolysis of the phosphate prodrugs of cytarabine.
59. Tobias SC, Borch RF. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharma 2004;1(2):112-6
60. Mehellou Y, Valente R, Mottram H, et al. Phophoramidates of 2¢-beta-Darabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. Bioorg Med Chem 2010;18:2439-46
61. Utreja P, Jain S, Tiwary AK. Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects. Curr Drug Deliv 2010;7(2):152-61
62. Diab R, Degobert G, Hamoudeh M, et al. Nucleoside analogue delivery systems in cancer therapy. Expert Opin Drug Deliv 2007;4(5):513-31. This review discusses the utility of different delivery systems useful for the nucleoside drugs in respective therapy.
63. Dubey SK, Pandey A, Mishra R, et al. Site directed drug delivery by non-viral mode. Ind J Biotech 2007;6(2):159-74
64. Kripp M, Hofheinz RD. Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine. Int J Nanomedicine 2008;3(4):397-401
65. Manjanna KM, Kumar TMP, Shivakumar B. Natural polysaccharide hydrogels as novel excipients for modified drug delivery systems: a review. Int J ChemTech Res 2010;2(1):509-25
66. Trigo RM, Blanco MD, Teijon JM, Sastre R. Anti-cancer drug, Ara-C, release from pHEMA hydrogels. Biomater 1994;15(14):1181-6
67. Sastre RL, Blanco MD, Gomez C, et al. Cytarabine trapping in poly(2-hydroxyethyl methacrylate-coacrylamide) hydrogels: drug delivery studies. Polym Int 1999;48:843-50
68. Kaasgaard T, Andresen TL. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv 2010;7(2):225-43
69. Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010;40(5):385-403
70. Bhattacharya S, Bajaj A. Advances in gene delivery through molecular design of cationic lipids. Chem Commun 2009;31:4632-56
71. Rao NM. Cationic lipid-mediated nucleic acid delivery: beyond being cationic. Chem Phys Lipids 2010;163(3):245-52
72. Maeda H, Wu J, Sawa T, et al. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84
73. Abu Lila AS, Ishida T, Kiwada H. Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharma Res 2010;27(7):1171-83
74. Dhamecha DL, Rathi AA, Saifee M, et al. Drug vehicle based approaches of penetration enhancement. Int J Pharm Pharm Sci 2009;1:24-46
75. Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharm 2008;9(2):301-9 . This review has a detailed analysis of reports related to liposomal formulation of cytarabine.
76. Mulik R, Kulkarni V, Murthy RSR. Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine. Drug Devel Ind Pharm 2009;35(1):49-56
77. Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 2008;9(2):301-9
78. Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J NeuroOncol 2007;81(2):201-8
79. Jaeckle KA, Batchelor T, ODay SJ. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neuro Oncol 2002;57(3):231-39
80. Bayne WF, Mayer LD, Swenson CE. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci 2009;98(7):2540-48
81. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009;33:129-39
82. Feldman E, Lancet J, Kolitz JE, et al. Phase I study of a liposomal carrier (CPX-351) containing an optimized, synergistic, fixed molar ratio of cytarabine and daunorubicin in advanced leukemias and myelodysplastic syndromes. Am Soc Hematol Ann Meet Blood 2007;110:900
83. Lima WS, Tardia PG, Santos ND. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010;34(9):1214-23
84. Schwendener R, Schott H. Lipophilic arabinofuranosyl cytosine derivatives in liposomes. Methods Enzymol 2005;391:58-70
85. Horber DH, Von Ballmoos P, Schott H, Schwendener RA. Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta- Darabinofuranosylcytosine. Br J Cancer 1995;72(5):1067-73
86. Horber DH, Schott H, Schwendener RA. Cellular pharmacology of a liposomal preparation of N4- hexadecyl-1-beta-Darabinofuranosylcytosine, a lipophilic derivative of 1-beta-Darabinofuranosylcytosine. Br J Cancer 1995;71(5):957-62
87. Rentsch KM, Schwendener RA, Schott H, Hanseler E. Pharmacokinetics of N4-octadecyl-1-beta-Darabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. J Pharm Pharmacol 1997;49(11):1076-81
88. Koller-Lucae SKM, Schott H, Schwendener RA. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-Darabinofuranosylcytosine, a new anticancer drug. J Pharmacol Exp Ther 1997;282(3):1572-80
89. Jancar J, Douglas JF, Starr FW, et al. Current issues in research on structure-property relationships in polymer nanocomposites. Polymer 2010;51(15):3321-43
90. Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine - an overview. Fundam Clin Pharmacol 2009;23(3):263-9
91. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010;75(1):1-18
92. Surendiran A, Sandhiya S, Pradhan SC, Adithan C. Novel applications of nanotechnology in medicine. Ind J Med Res 2009;130(6):689-701
93. Rukmani K, Sivakumar M, Kumar SS. Nanoparticular drug delivery system of cytarabine hydrochloride (CTH) for improved treatment of Lymphoma. J Biomed Nanotech 2007;3(1):90-6
94. Blanco MD, Gomez C, Olmo R, et al. Chitosan microspheres in PLG films as devices for cytarabine release. Intern J Pharma 2000;202:29-39
95. Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target 2009;17(9):671-89
96. Sagar GH, Arunagirinathan MA, Bellare JR. Self assembled surfactant nano-structures important in drug delivery: a review. Ind J Exp Biol 2007;45:133-59
97. Ruckmani K, Ghosal SK. The efficacy of 1-beta-D-arabinofuranosylcytosine entrapped in niosomes against leukaemia in mice. STP Pharma Sci 2001;11(4):301-3